← All trials
NCT02943642
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 1, 2017
- Primary completion
- Dec 1, 2018
- Completion date
- May 1, 2020
- First posted
- —
- Last posted
- —
- Enrollment
- 162
- Arms / groups
- 3 / —
- Source
- AACT · pre-existing
Sponsors
- Angimmune LLCLead sponsor
- Columbia UniversityCollaborator
- Yale UniversityCollaborator
- Stanford UniversityCollaborator
- Thomas Jefferson UniversityCollaborator
- University of WashingtonCollaborator
- University of South FloridaCollaborator
- Rush UniversityCollaborator
- Hoosier Cancer Research NetworkCollaborator
- The University of Texas, DallasCollaborator
- City of Hope National Medical CenterCollaborator
- Northwestern UniversityCollaborator
- Ohio State UniversityCollaborator
- Vanderbilt UniversityCollaborator
- Harvard UniversityCollaborator
- Washington University in St. LouisCollaborator
- Scott and White HealthcareCollaborator
- University of Colorado, DenverCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.